Skip to main content

Eicosapentaenoic and docosahexaenoic acids attenuate hyperglycemia through the microbiome-gut-organs axis in db/db mice

Abstract

Background

Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) have been suggested to prevent the development of metabolic disorders. However, their individual role in treating hyperglycemia and the mechanism of action regarding gut microbiome and metabolome in the context of diabetes remain unclear.

Results

Supplementation of DHA and EPA attenuated hyperglycemia and insulin resistance without changing body weight in db/db mice while the ameliorative effect appeared to be more pronounced for EPA. DHA/EPA supplementation reduced the abundance of the lipopolysaccharide-containing Enterobacteriaceae whereas elevated the family Coriobacteriaceae negatively correlated with glutamate level, genera Barnesiella and Clostridium XlVa associated with bile acids production, beneficial Bifidobacterium and Lactobacillus, and SCFA-producing species. The gut microbiome alterations co-occurred with the shifts in the metabolome, including glutamate, bile acids, propionic/butyric acid, and lipopolysaccharide, which subsequently relieved β cell apoptosis, suppressed hepatic gluconeogenesis, and promoted GLP-1 secretion, white adipose beiging, and insulin signaling. All these changes appeared to be more evident for EPA. Furthermore, transplantation with DHA/EPA-mediated gut microbiota mimicked the ameliorative effect of DHA/EPA on glucose homeostasis in db/db mice, together with similar changes in gut metabolites. In vitro, DHA/EPA treatment directly inhibited the growth of Escherichia coli (Family Enterobacteriaceae) while promoted Coriobacterium glomerans (Family Coriobacteriaceae), demonstrating a causal effect of DHA/EPA on featured gut microbiota.

Conclusions

DHA and EPA dramatically attenuated hyperglycemia and insulin resistance in db/db mice, which was mediated by alterations in gut microbiome and metabolites linking gut to adipose, liver and pancreas. These findings shed light into the gut-organs axis as a promising target for restoring glucose homeostasis and also suggest a better therapeutic effect of EPA for treating diabetes.

Video abstract

Background

Type 2 diabetes (T2D), an obesity-related metabolic disease, is rising exponentially throughout the world [1]. Genetic susceptibility and lifestyle factors are recognized as the main cause of T2D. Intriguingly, recent evidence suggests non-communicable chronic diseases, such as diabetes, could be communicable via dysbiotic microbiota, as demonstrated by fecal microbiota transplant (FMT) studies [2,3,4]. Previous literature has also revealed a critical role of dietary factors, including dietary fat [5], in shaping gut microbial composition. Increased consumption of saturated fat induces intestinal dysbacteriosis and endotoxemia [6, 7], whereas polyunsaturated fatty acids (PUFAs) restore gut micro-ecological equilibrium and relieve inflammation [8,9,10,11]. Notably, emerging evidence shows that marine n-3 PUFAs, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are able to ameliorate insulin resistance (IR) in rodents probably via regulating adipocytokines secretion [12,13,14], inhibiting adipose remodeling [15], lowering inflammation [16,17,18], and enhancing mitochondrial function and β-oxidation [19]. Although fish oil, rich in n-3 PUFAs, was reported to alter intestinal microbiota composition [10, 20, 21], another study showed that n-3 PUFAs did not protect against gut microbiota dysbiosis in mice [22]. Importantly, data regarding the individual effect of DHA versus EPA on the gut microbiome in the context of diabetes is absent.

Emerging evidence suggests a complex interplay between gut and host organs [23,24,25,26], including adipose, liver, and pancreas. Gut dysbiosis increases the influx of lipopolysaccharide (LPS), which further triggers systemic inflammation and IR by activating toll-like receptor 4 (TLR4) [27]. In addition, the microbiota-derived metabolites short-chain fatty acids (SCFAs), including propionate and butyrate, promote the glucagon-like peptide-1 (GLP-1) production from intestinal L cells and thereby improve the release of insulin from the pancreas [28, 29]. SCFAs are also signaling molecules that benefit metabolic health via activating G-protein coupled receptors (GPRs) [30]. Intestinal microbiota was also found to be capable of regulating enterohepatic bile acids (BAs) metabolism by biotransforming BAs into forms that possess potent regulatory effects on BA signaling receptors [31, 32]. Glutamate-fermenting commensal contributes to the improved metabolic health in obesity, probably by damping glutamate-induced IR [33]. Therefore, gut microbiota manipulated by dietary factors may, in turn, impact the host metabolism via microbiota-derived metabolites. However, how n-3 PUFAs affect gut metabolome remains poorly understood.

In the present study, we aimed to investigate the individual effects of DHA and EPA supplementation on glucose metabolism and possible crosstalk between gut and adipose, liver, and pancreas in the context of diabetes. To examine this hypothesis, we assessed the changes in the gut microbiome and metabolome in response to DHA/EPA supplementation in db/db mice and FMT was further applied to determine whether the beneficial effect was driven by gut microbiota and metabolites linking gut to adipose, liver, and pancreas. Finally, featured gut microbial species were treated with DHA/EPA in vitro to confirm whether DHA/EPA could directly affect their growth.

Results

EPA and DHA attenuate hyperglycemia and enhance energy expenditure in db/db mice

To assess how DHA and EPA affect glucose homeostasis, we fed db/db mice isocaloric diets that were control diet (CD) supplemented with 1% (w/w) EPA or DHA for 10 weeks (Additional file 1: Table S1). Although food intake and weight gain were not affected during the intervention (Fig. 1a, b and Additional file 1: Figure S1a), both DHA and EPA supplemented mice exhibited significantly lower fasting glucose and HbA1c levels and a higher insulin level compared with db/db mice fed CD (Fig. 1c, f, i) after the treatment. Results from the oral glucose tolerance test (OGTT) and insulin tolerance test (ITT) demonstrated that both DHA and EPA improved glucose tolerance while EPA markedly increased insulin sensitivity (Fig. 1d, e, g, h). Additionally, EPA-fed mice had a higher pyruvate tolerance (Fig. 1j, k), which indicated inhibited gluconeogenesis. Together, treatment with DHA/EPA partially restored glucose homeostasis in db/db/ mice while EPA manifested a more potent ameliorative effect than DHA.

Fig. 1
figure1

Differential effects of DHA and EPA on glucose homeostasis and metabolic profile in db/db mice. The db/db mice were fed either a control diet (db/db), DHA-enriched diet (db/db + DHA), or EPA-enriched diet (db/db + EPA) for 10 weeks (n = 6 male and n = 6 female per group). a, b Body weight curves. c Serum glucose levels. d, e, g, h, j, k Time-dependent profiles of serum glucose levels in OGTT, ITT, and PTT with AUC. f Blood HbA1c levels. i Serum insulin levels. l Serum TG levels. m–p Oxygen consumption. q–t RER. Data are presented as the mean ± SEM. Data with different superscript letters are significantly different (P < 0.05) using one-way ANOVA followed by Tukey’s multiple comparison post-test. P values in m–t were assessed by two-way ANOVA

Regarding lipid metabolism, we observed EPA-fed female mice had significantly reduced levels of TG, TC, and LDL-C (Fig. 1l and Additional file 1: Figure S1d, e, and f). Although DHA/EPA supplementation did not change white adipose tissue (WAT) mass, interscapular brown adipose mass was enlarged by EPA and DHA (Additional file 1: Figure S1b, c). It is noteworthy that both DHA and EPA elevated oxygen consumption and decreased RER (Fig. 1m–t), indicative of enhanced energy expenditure and fat utilization.

DHA and EPA differentially alter the gut microbiome

The effectiveness of the EPA/DHA intervention was verified by the dramatic increase in tissue levels of DHA and EPA (Additional file 1: Figure S2a). Meanwhile, we detected significant changes in antimicrobial peptide production in the small intestine: DHA feeding markedly increased the expression of α-defensin–Defa in male and female mice and Reg3g in females. The expressions of α-defensin–Defa, Pla2g2a, and Reg3g were upregulated 2.5–20-fold by EPA supplementation (Additional file 1: Figure S2b, c). Therefore, we performed 16S rRNA gene sequencing to analyze the differences in gut microbial ecology between groups.

Compared with WT mice, db/db mice had substantially lower bacterial richness whereas DHA and EPA feeding partially restored the phylogenetic diversity indicated by Chao1 (Additional file 1: Figure S3a–d). Principal coordinate analysis (PCoA) revealed distinct clustering of WT, db/db, and db/db + DHA/EPA groups (Additional file 1: Figure S3e, f), whereas EPA and DHA groups were not clearly separated. At the phylum level, DHA and EPA feeding significantly enriched Verrucomicrobia and Deferribacteres phyla in male mice while Bacteroidetes phylum was greater in DHA/EPA-fed female mice (Additional file 1: Figure S3g, h).

We further performed linear discriminant analysis effect size (LEfSe) (LDA > 2) to identify taxa that may be microbiological markers for db/db, db/db + DHA, and db/db + EPA groups (Fig. 2a, b). In male mice, DHA and EPA supplementation significantly elevated the abundances of phylotypes Coriobacteriaceae, Desulfovibrionaceae, and Prevotella while reduced Enterobacteriaceae, Bacillales, Lactobacillales, Staphylococcus, Streptococcus, Enterococcus, Parabacteroides, Weissella, Blautia, and Faecalibacterium. Moreover, DHA specifically enriched Alloprevotella and Enterorhabdus while EPA specifically enriched Deferribacteraceae, Barnesiella, Odoribacter, Mucispirillum, Clostridium lV, and Eubacterium. In female mice, DHA and EPA feeding reduced the abundances of Enterobacteriaceae, Clostridiales, Klebsiella, Raoultella, and Roseburia. Additionally, DHA-fed female mice had more abundant Coriobacteriaceae, Deferribacteraceae, Bifidobacterium, Enterorhabdus, Mucispirillum, and Clostridium XlVa. EPA-fed female mice had greater species from Barnesiella, Lactobacillus, Clostridium Xl, Intestinimonas, Erysipelotrichaceae, Allobaculum, and Turicibacter. Heatmaps also reveal differential OTUs from the above phylotypes between three groups in males and females, respectively (Fig. 2c, d). Altogether, these findings demonstrated that DHA and EPA differentially modulated the dysbiosis of gut microbiota in db/db mice.

Fig. 2
figure2

DHA and EPA differentially alter gut microbial phylotypes in db/db mice. Fecal microbiota composition in mice from different groups were analyzed using 16S rDNA sequencing (n = 6 male and n = 5-6 female per group). a, b Cladogram obtained from LEfSe analysis (LDA > 2), showing the most differentially abundant taxa enriched in microbiota from mice in db/db (blue), db/db + DHA (green), and db/db + EPA (red) groups. c, d Heatmap showing OTUs with significantly different relevant abundances between three treatment groups (as determined by Kruskall-Wallis test followed by Mann–Whitney test). Each row represents an OTU labeled by the lowest taxonomic description and OTU ID, normalized to the row maximum

EPA and DHA modulate gut metabolome

Gut microbiota interacts with metabolites to impact the host metabolism [34]. We predicted changes in metabolic functions within the microbiome by Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis of differentially expressed genes between DHA/EPA and db/db groups. Results showed that the pathways of ‘‘D-glutamine and D-glutamate metabolism’’ and ‘‘primary/secondary bile acid biosynthesis’’ were consistently upregulated by DHA/EPA treatment in male and female mice (Additional file 1: Figure S4). Therefore, we assessed the potential differences in fecal metabolite profiles between the three groups by an untargeted metabolomics approach. The partial least squares discriminant analysis (PLS-DA) showed a clear separation between the three groups according to the abundance of fecal metabolites (Fig. 3a, b). To maximize the discrimination between DHA/EPA-treated mice and CD-fed mice, we next performed pairwise OPLS-DA on the fecal metabolome data from these groups. As revealed by the volcano plots, substantial metabolic changes occurred after DHA/EPA supplementation in db/db mice (Fig. 3c, e, g, i). Among the significantly changed molecules (marked in black), we noted that l-glutamic acid, taurine-conjugated (T) cholic acid (CA), and chenodeoxycholic acid (CDCA) were markedly decreased while 2-oxoglutaric acid, CA, CDCA, and deoxycholic acid (DCA) were increased in DHA/EPA-fed db/db mice, which was in accordance with the KEGG analysis of microbiome. Consistently, when we performed integrated pathway analysis by mapping all the differential annotated metabolites into biochemical pathways, multiple pathways were perturbed including ‘‘D-glutamine and D-glutamate metabolism’’ and ‘‘primary/secondary bile acid biosynthesis’’ (Fig. 3d, f, h, j). Intriguingly, glutamate and bile acid metabolism have been implicated in the pathology of metabolic syndrome.

Fig. 3
figure3

DHA and EPA differentially modulate gut metabolome in db/db mice. Global metabolic profiling on fecal was performed by UHPLC-Q-Orbitrap-HRMS (n = 5 male and n = 5 female per group). a Three-dimensional (3D) view of PCA score plot by UHPLC-Q-Orbitrap-HRMS analysis in male mice (combination of ions from positive and negative ion modes. R2X = 0.67, Q2 (cum) = 0.55). b 3D view of PCA score plot in female mice (R2X = 0.59, Q2 (cum) = 0.46). c, e Volcano plot (based on the combination of ions from positive and negative ionization modes) between db/db + DHA and db/db groups. g, i Volcano plot between db/db + EPA and db/db groups. Black points in the volcano plot represent significantly different metabolites which include key metabolites (highlighted in red) involved in glutamate metabolism and bile acid metabolism. d, f Pathway impact resulting from the differential metabolites (obtained from OPLS-DA model with VIP > 1) using MetaboAnalyst in DHA-fed mice. h, j Pathway impact resulting from the differential metabolites in EPA-fed mice. Small P value and big pathway impact factor indicate that the pathway is greatly influenced. Pathways of glutamate metabolism and bile acid metabolism were perturbed by DHA/EPA

DHA and EPA rescue glutamate-induced β cell apoptosis

Given that DHA/EPA impacted glutamate metabolism which has been linked with metabolic disorders [33, 35], we further specifically compared the fecal content of l-glutamine, l-glutamate, γ-aminobutyric acid (GABA), and 2-oxoglutaric acid involved in the ‘‘D-glutamine and D-glutamate metabolism’’ pathway between the treatment groups (Fig. 4a). Although fecal levels of GABA and l-glutamine were not affected by DHA/EPA, l-glutamate level in fecal was significantly reduced in DHA-fed female mice and EPA-fed male and female mice. Conversely, the fecal 2-oxoglutaric acid level was elevated in EPA-receiving mice, while a trend toward a higher level of 2-oxoglutaric acid was detected in DHA-fed mice. In addition, we also observed similar changes in serum levels of l-glutamate and 2-oxoglutaric acid (Additional file 1: Figure S5a, b). Notably, microbial genes encoding glutamate dehydrogenase (K00261) which converses glutamate to 2-oxoglutaric acid was upregulated by DHA/EPA (Fig. 4a).

Fig. 4
figure4

DHA/EPA accelerates glutamate degradation and rescues glutamate-induced β cell apoptosis. a Schematic overview of the differential metabolites involved in glutamate metabolism (n = 5 male and n = 5 female per group). Red circle represents up-regulated metabolites, blue circle represents downregulated metabolites, and open circle represents no change. Microbial gene encoding glutamate dehydrogenase (K00261) was upregulated by DHA/EPA. b, c Representative images of insulin staining in pancreases. Scale bar, 100 μm. d, e Apoptosis of β cell was determined by ELISA. Data are normalized to the db/db group (n = 6 male and n = 6 female per group). f, g mRNA expression of GLT1 and inflammatory cytokines in the pancreas. Groups with different superscript letters are significantly different (P < 0.05)

Chronic exposure to glutamic acid has been evidenced to exert a cytotoxic effect on β cell via activation of the glutamate transporter 1 (GLT1) [36]. Therefore, we then analyzed β cell apoptosis in the pancreas. Insulin immunohistochemistry showed that DHA/EPA rescued the β-cell death to some extent (Fig. 4b, c), which was further confirmed by a quantitative apoptosis assay (Fig. 4d, e). Moreover, we observed suppressed expression of GLT1 in DHA/EPA-fed mice with decreased expressions of inflammatory TNF-α, IL6, and CCL2 (Fig. 4f, g). Overall, EPA supplementation showed more pronounced changes compared with DHA. These findings indicate DHA/EPA supplementation enriched intestinal microbial species that possessed glutamate dehydrogenase to facilitate the degradation of glutamate and thereby prevented β cell apoptosis in db/db mice.

DHA and EPA modulate bile acid metabolism and suppress hepatic gluconeogenesis

The gut microbiota-bile acid interaction plays a key role in regulating host lipid and glucose homeostasis [32]. We detected DHA/EPA enriched microbial genes encoding BSH (K01442) which deconjugated taurine-conjugated bile acids to form unconjugated bile acids (Fig. 5a). Consistently, we observed reduced fecal levels of TCA and TCDCA and increased levels of CA and CDCA in DHA/EPA-fed mice. Interestingly, DHA/EPA supplementation did not affect CA levels whereas substantially elevated DCA levels in female mice. Fecal UDCA level was not altered by DHA/EPA. Similar changes in these bile acids were also observed in serum (Additional file 1: Figure S5c–g).

Fig. 5
figure5

DHA/EPA influences bile acid metabolism and suppresses hepatic gluconeogenesis. a Schematic overview of the differential metabolites involved in bile acid metabolism (n = 5 male and n = 5 female per group). Red circle represents upregulated metabolites, blue circle represents downregulated metabolites, and open circle represents no change. Microbial gene encoding BSH (K01442) was upregulated by DHA/EPA. b Hepatic PEPCK concentrations. c Hepatic G6PC concentrations. d Hepatic GP concentrations. e, f Hepatic mRNA expression of FXR, SHP, FOXO1, and HNF4. g Representative hepatic immunoblots for FXR, SHP, p-FOXO1, and t-FOXO1. Groups with different superscript letters are significantly different (P < 0.05)

Bile acids regulate hepatic glucose and lipid metabolism through modulating FXR [37]. We first observed that DHA/EPA administration significantly decreased the activity of hepatic PEPCK and G6PC involved in gluconeogenesis and EPA reduced GP involved in glycogenolysis (Fig. 5b–d). Next, we examined whether FXR-SHP-FOXO1 pathway was regulated. As anticipated, hepatic mRNA levels of FXR and SHP were promoted in DHA/EPA-fed mice (Fig. 5e, f). Western blot further verified that DHA/EPA supplementation increased protein expressions of FXR and SHP while induced the phosphorylation of FOXO1 (Fig. 5g). All these changes seemed stronger in EPA-fed mice compared with DHA-fed mice. Thus, these data suggest that DHA/EPA enriched BSH-positive gut microbiota and species that accelerated the production of unconjugated CA, CDCA, and secondary bile acid DCA, which activated FXR-SHP-FOXO1 pathway to inhibit hepatic gluconeogenesis.

FXR activation also regulates hepatic lipid homeostasis [32]. We also found decreased hepatic TG concentration despite unchanged TC, HDL-C, and LDL-C levels in DHA/EPA-fed mice (Additional file 1: Figure S6a–d). Liver sections of db/db mice showed DHA/EPA administration dramatically mitigated the extensive vacuolization, suggesting suppressed lipid accumulation (Additional file 1: Figure S6e, f). Subsequently, we observed mRNA expression of FASN associated with lipogenesis was consistently downregulated by DHA and EPA supplementation in male and female mice (Additional file 1: Figure S6g, h). Furthermore, DHA and EPA mitigated hepatic inflammation, which was indicated by immunofluorescence staining of F4/80 and decreased expressions of TLR4 and CCL2 (Additional file 1: Figure S6i–l).

DHA and EPA promote SCFA production and beiging of WAT

In light of significant changes in levels of propionic acid and butyric acid by DHA/EPA in UHPLC data of fecal content, we further assessed SCFA concentrations using GC. Results verified that propionate concentration was elevated by DHA and both propionate and butyrate were increased by EPA in male and female mice despite the unchanged levels of acetate and valerate (Fig. 6a). We also detected markedly increased concentration of GLP-1 by DHA and EPA administration in ileum and jejunum (Fig. 6b, c). SCFA production was proposed to stimulate the secretion of GLP-1 from L cells. Here, we verified that administration of propionate and butyrate could directly affect GLP-1 production in db/db mice (Additional file 1: Figure S7). Administration of butyrate significantly increased the production of GLP-1 in ileum and jejunum of db/db mice. Propionate supplementation showed a similar effect but was weaker than butyrate. EPA supplementation also significantly alleviated endotoxin in db/db mice (Fig. 6d). Accordingly, higher mRNA expressions of GPR41 and GPR43 and lower TLR4 expression was noted in the adipose tissue of DHA/EPA-treated mice (Fig. 6e). Moreover, mRNA expressions of proinflammatory IL6 and CCL2 in WAT were suppressed by DHA/EPA.

Fig. 6
figure6

EPA and DHA promote SCFA production and beiging of WAT (n = 6 male and n = 6 female per group). a Individual SCFA levels in cecum content. b, c GLP-1 concentrations in small intestinal. d Serum LPS levels. e mRNA expression of TLR4, GPR41, GPR43, IL6, and CCL2 in WAT. f Representative images of UCP1 and CD137 staining in adipose tissues. Scale bar, 100 μm. g Representative adipose immunoblots for UCP1, CD137, PRDM16, and PPARγ. h Representative adipose immunoblots for GLUT4, p-AKT, and t-AKT. Graph bars with different superscript letters are significantly different (P < 0.05)

SCFA production was shown to attenuate inflammation and induce beiging of WAT [38, 39]. Subsequently, DHA and EPA supplementation markedly enhanced UCP1 and CD137 expressions as revealed by immunohistochemistry and western blot in inguinal WAT (Fig. 6f, g). Moreover, beiging program marker PRDM16 and PPARγ were also upregulated in DHA/EPA-fed mice (Fig. 6g). Finally, we observed evidently increased phosphorylation of Akt despite the unchanged expressions of GLUT4 in WAT, indicative of promoted GLUT4 translocation by DHA/EPA (Fig. 6h). Taken together, these findings suggest that DHA/EPA enhanced the generation of propionate and butyrate while alleviated endotoxin and inflammation and, subsequently, promoted WAT beiging and insulin signaling.

DHA/EPA-altered gut microbes correlate with key metabolites

To determine the functional relationship between the DHA/EPA-altered gut microbes and metabolites, an inter-omic network was constructed using microbiome and metabolome and showed 250 strong correlations (|Spearman’s non-parametric rank correlation coefficient|> 0.6 and p < 0.05) between microbe (genera) and metabolite (Additional file 1: Figure S8). We identified genera Coriobacteriaceae, Barnesiella, and Clostridium XlVa showing strong correlations with fecal glutamate/bile acids from the network. Among these genera, the species Coriobacteriaceae (OTU19898) exhibited the highest negative correlation with glutamate acid (r2 = 0.50, p < 0.0001) and positive correlation with 2-oxoglutaric acid (r2 = 0.48, p < 0.0001) (Fig. 7a, b). In addition, the abundance of Barnesiella (OTU136) was inversely associated with taurine-conjugated bile acids (TCA + TCDCA) (r2 = 0.47, p < 0.0001) while Clostridium XlVa (OTU57) was positively related to fecal DCA level (r2 = 0.47, p < 0.0001) (Fig. 7c, d). These three key microbial species have been enriched in DHA/EPA-fed mice (Fig. 2c, d). Thus, these findings revealed the potential interactions between DHA/EPA-modulated microbial species and glutamate/bile acids.

Fig. 7
figure7

Transplantation of DHA/EPA-altered microbiota restores glucose homeostasis (n = 5 male and n = 5 female per group). a–d Linear regression analysis of fecal glutamate/bile acids with OTUs from genera identified in the microbe–metabolite network analysis. Fecal glutamate/bile acids show strong correlations with Coriobacteriaceae (OTU19898), Barnesiella (OTU136) and Clostridium XlVa (OTU57). e–g Relative abundance of Coriobacteriaceae (OTU19898), Barnesiella (OTU136), and Clostridium XlVa (OTU57) in db/db mice after fecal transplantation. Fecal transplantation from DHA/EPA-fed mice to db/db mice was performed as described in the “Methods” section. h Body weight curves for male mice during fecal transplantation. i Body weight curves for female mice during fecal transplantation. j Serum glucose levels after fecal transplantation. k Blood HbA1c levels. l Serum insulin levels. m Fecal l-glutamic acid levels. n Fecal 2-oxoglutaric acid levels. o mRNA expression of GLT1 in the pancreas. p Apoptosis of β cell normalized to the db/db group. q Fecal TCDCA levels. r Fecal TCA/TMCA levels. s Fecal CA/MCA levels. t Fecal CDCA levels. u Fecal DCA levels. v Hepatic mRNA expression of FXR, SHP, PEPCK, and G6PC. Groups with different superscript letters are significantly different (P < 0.05)

Gut microbiota orchestrates DHA/EPA-induced glucose homeostasis restoration

To investigate whether the DHA/EPA-induced intestinal microbial shift directly contributes to improved glucose metabolism, microbiota from DHA/EPA supplemented mice (referred as DHA/EPA-microbiota) were transplanted to microbiota-depleted db/db male and female mice. First, we validated the effect of antibiotic treatment on recipient db/db mice (Additional file 1: Figure S9). After transplantation with DHA/EPA-microbiota, recipient mice showed a similar pattern of gut microbial changes with DHA/EPA-fed mice (Additional file 1: Figure S10). Notably, the abundance of Coriobacteriaceae (OTU19898) and Barnesiella (OTU136) were remarkably elevated in mice transplanted with DHA/EPA-microbiota, and Clostridium XlVa (OTU57) was enriched in transplanted female mice (Fig. 7e–g), indicating the successful microbiota transplantation. Although the bodyweight gain was not affected, transplantation with DHA/EPA-microbiota significantly lowered the fasting glucose and Hb1Ac levels along with increased insulin level (Fig. 7h–l). In line with the enrichment of DHA/EPA-induced microbial species, we also detected decreased fecal levels of l-glutamic acid and increased 2-oxoglutaric acid. Accordingly, GLT1 expression was downregulated and β-cell death was mitigated in mice transplanted with DHA/EPA-microbiota (Fig. 7o, p). In addition, fecal taurine-conjugated bile acids were reduced while CA, CDCA, and DCA were increased in transplanted mice (Fig. 7q–u). Accordingly, hepatic mRNA expressions of FXR and SHP were promoted while PEPCK and G6PC expressions were inhibited by DHA/EPA-microbiota transplantation (Fig. 7v). Furthermore, transplanted mice also had higher fecal levels of propionate and butyrate, increased GLP-1 release in small intestinal and lower serum LPS concentration (Additional file 1: Figure S11a–c). As expected, we observed decreased TLR4 expression in WAT of EPA-microbiota transplanted mice and elevated expressions of GPR41 and GPR43 in DHA and EPA-microbiota transplanted mice (Additional file 1: Figure S11d). Moreover, adipose mRNA expressions of beiging markers including UCP1, CD137, PRDM16, and PPARγ were all significantly enhanced (Additional file 1: Figure S11e). All these alterations were more pronounced in EPA-microbiota-transplanted mice. Altogether, these results underscore the vital role of gut microbiota in the effects of DHA/EPA on preventing β cell apoptosis, suppressing hepatic gluconeogenesis, promoting GLP-1 secretion and inducing WAT beiging, which subsequently improved glucose homeostasis.

DHA/EPA directly affect the growth of gut bacteria in vitro

To further evaluate the causal effect of DHA/EPA supplementation on the growth of specific gut microbiota, we selected pure cultures of Escherichia coli (Family Enterobacteriaceae) and Coriobacterium glomerans (Family Coriobacteriaceae) which were featured microbiological markers of db/db and db/db + DHA/EPA groups, respectively, and conducted in vitro intervention experiments. The bacterial growth media were added with DHA or EPA at 200 µM which was in a physiological range [40, 41]. As shown in Fig. 8a, supplementation of DHA and EPA significantly reduced the growth rates of Escherichia coli and the bacterial cell density for EPA group was lower than that of DHA group at the stationary growth phase, indicating a more potent antimicrobial activity of EPA. As regards to Coriobacterium glomerans, DHA and EPA similarly increased the bacterial cell density during the incubation period (Fig. 8b). These data demonstrated that DHA/EPA could directly inhibit the growth of Escherichia coli while promote Coriobacterium glomerans, which thereby drove the metabolic benefits.

Fig. 8
figure8

Effect of EPA and DHA on the growth of Escherichia coli and Coriobacterium glomerans in vitro. Strain Escherichia coli (a) was grown in LB medium and Coriobacterium glomerans (b) was grown in Gifu anaerobic medium. Media were added with DHA (200 µM), EPA (200 µM) or vehicle. Cell density of cultures was recorded at the indicated time points. Data are presented as the mean ± SEM (n = 6). P values were assessed by two-way ANOVA (*P < 0.05, **P < 0.01, ***P < 0.001)

Discussion

In this study, DHA/EPA supplementation was found to dramatically attenuate hyperglycemia and IR in db/db mice. This amelioration was mediated by gut microbiome alterations and metabolites including glutamate, bile acids, and SCFAs, which led to relieved β cell apoptosis, suppressed hepatic gluconeogenesis, enhanced GLP-1 production, and WAT beiging. Overall, EPA displayed a more pronounced therapeutic effect through the interactions between gut and pancreas, liver, and adipose.

Although replacing dietary fat with n-3 PUFAs has been reported to effectively prevent the development of hyperglycemia in dietary obese rodents [42,43,44,45,46,47], few studies have investigated the possible therapeutic action of n-3 PUFAs on impaired glucose homeostasis. A previous study in rats found no protective effect of n-3 PUFAs supplementation on already established IR [48], whereas EPA administration was shown to minimize saturated fat induced IR and enhance fatty acid oxidation [16]. Here, we further demonstrated that DHA/EPA supplementation was able to attenuate hyperglycemia and restore impaired glucose homeostasis in db/db mice while the ameliorative effect was more potent for EPA. Similarly, the same low dose of EPA but not DHA was evidenced to protect against glucose intolerance in obese mice [14]. Together, these results suggest a promising role of EPA rather than DHA in diabetes treatment and management.

Previous studies have shown that fish oil containing EPA and DHA improved intestinal dysbacteriosis and influenced the gut microbiota content [10, 20, 21]. Compared with wild-type mice, fat-1 transgenic mice which endogenously convert n-6 to n-3 PUFAs had less abundant Ruminococcus but more abundant Akkermansia, S24-7, and Tenericutes [49]. Here, we showed both DHA and EPA increased the diversity and modulated the composition of gut microbiota while the similarities and differences in their effects on gut microbiome were also documented. Notably, both DHA and EPA reduced the abundance of the LPS-containing Enterobacteriaceae [20] and some pathogenic bacteria, including Staphylococcus, Streptococcus, and Klebsiella [50,51,52]. It is believed that gram-negative Enterobacteriaceae can release LPS, resulting in systemic subclinical inflammation and thereby impairing insulin sensitivity [53]. Streptococcus infection could induce divergent phagocyte programmed cell death and cause robust inflammatory responses [52]. DHA and EPA elevated SCFA-producing Prevotella [54] and the family Coriobacteriaceae which was decreased in diabetic patients [55]. Prevotella is known to produce anti-inflammatory propionate, which could regulate the differentiation of anti-inflammatory Treg/Tr1 cells [54]. Additionally, DHA specifically enriched Enterorhabdus which was previously identified in non-diabetic lean animals [56], SCFA-producing Alloprevotella [57], and Clostridium XlVa which was depleted in inflammatory bowel diseases [58], while EPA specifically enriched anti-inflammatory Barnesiella [59] and Mucispirillum [60], Clostridium lV which has been negatively associated with obesity [61], Allobaculum negatively correlated with IR [62] and butyrate-producing Eubacterium [63] and Intestinimonas [64]. Barnesiella was correlated with several immunoregulatory cells and suggested to render the gut environment less prone to inflammation [59]. Allobaculum [65] and Eubacterium [66] induced by probiotics supplementation exerted beneficial physiological effects on obese animals, underscoring the probiotic potential of these species. Notably, beneficial bacteria Bifidobacterium and Lactobacillus were promoted by DHA and EPA respectively in female db/db mice. Bifidobacterium and Lactobacillus have been reported to improve gut integrity and counteract endotoxemia and inflammation [67,68,69]. These substantial shifts in gut community structure induced by DHA and EPA may maintain the intestinal health and impact microbial metabolites production.

KEGG analyses of gut microbiome and metabolome consistently demonstrated that glutamate metabolism and bile acid metabolism were the key metabolic pathways modified by DHA/EPA. Administration of glutamate has been shown to induce adiposity and impair glycemic control in rodents [70, 71]. Mechanically, the elevated glutamic acid level was found to induce pancreatic β cell apoptosis through GLT1 [36, 72]. Previous studies also revealed a link between gut microbiome and glutamate metabolism [73, 74]. A recent intervention study demonstrated that gavage with B. thetaiotaomicron which carried glutamate decarboxylase reduced plasma glutamate and ameliorated metabolic syndrome in diet-induced obese mice [33], indicating a promising role of targeting gut microbiota in obesity management via glutamate metabolism regulation. Here, we found l-glutamate level was substantially decreased and glutamate-induced β cell apoptosis was rescued especially by EPA. Correlation analysis further discovered the species Coriobacteriaceae (OTU19898) exhibited the highest negative correlation with l-glutamate acid and positive correlation with 2-oxoglutaric acid. The family Coriobacteriaceae has been suggested to play an important role in glucose metabolism regulation [75]. Coriobacterium glomerans, a species from Coriobacteriaceae, was found to possess glutamate dehydrogenase (K00261) which conversed glutamate to 2-oxoglutaric acid [76]. In vitro, we detected that DHA and EPA directly promoted the growth of Coriobacterium glomerans. Therefore, we speculate that the protective effect of DHA/EPA supplementation on β cell apoptosis was driven by Coriobacteriaceae (OTU19898) that possessed glutamate dehydrogenase to accelerate glutamate degradation.

The interaction between gut microbiota and bile acids plays a key role in regulating host metabolism [32]. Primary bile acids are initially synthesized in the liver, predominantly conjugated with taurine in mice, and subsequently deconjugated and metabolized by the intestinal microbiota into secondary bile acids, which affects FXR activation and signaling [32]. The primary bile acid CDCA is the strongest agonist for FXR followed by CA, the secondary bile acid DCA, and LCA [77], while the murine taurine-conjugated bile acids TMCA antagonize FXR [78]. Activation of FXR was shown to improve hyperlipidemia and hyperglycemia in db/db mice by repressing hepatic gluconeogenesis and increasing glycogen synthesis [79]. Furthermore, bile acids were evidenced to regulate hepatic gluconeogenic gene expression via the FXR-SHP-FOXO1 regulatory pathway [80]. In our study, we showed DHA/EPA supplementation elevated CDCA and CA whereas reduced TCA levels along with activated FXR-SHP-FOXO1 pathway and suppressed hepatic gluconeogenesis. Notably, the abundance of Barnesiella (OTU136) was inversely associated with taurine-conjugated bile acids, indicating Barnesiella (OTU136) produced BSH (K01442) activity which deconjugated taurine-conjugated bile acids to form unconjugated bile acids. Additionally, DCA level was positively related to Clostridium XlVa (OTU57) which could be capable of producing secondary bile acids via dehydrogenation, dehydroxylation, and isomerization processes [32]. Taken together, we reason that DHA/EPA enriched BSH-producing Barnesiella (OTU136) and Clostridium XlVa (OTU57) that promoted the production of unconjugated CA, CDCA, and secondary bile acid DCA, which inhibited hepatic gluconeogenesis via FXR-SHP-FOXO1 pathway.

The interplay between gut and adipose tissue [23, 24] affects white adipose inflammation which subsequently participates in the IR development [81]. We also noted DHA/EPA administration reduced endotoxemia and promoted SCFA production, mainly propionic and butyric acids, which could be attributed to reduced LPS-containing Enterobacteriaceae [20] and increased propionic/butyric acid-producing taxa Prevotella [54], Alloprevotella [57], Clostridium XlVa [58], Eubacterium [63], and Intestinimonas [64]. Propionic acid supplementation was reported to alleviate inflammation and improve glucose uptake in WAT from overweight adults [82]. Treatment of butyric acid also mitigated IR in mice [83] and attenuated inflammation through GPR41 and interaction with macrophages in 3T3-L1 adipocytes [84]. In contrast, increased production of acetic acid promoted metabolic syndrome in high fat diet (HFD)-fed mice via parasympathetic activation [85]. Accordingly, we detected increased expression of corresponding SCFA receptors (GPR41 and GPR43) in WAT and enhanced insulin signaling especially by EPA. Moreover, SCFAs supplementation was shown to promote beige adipogenesis, mitochondrial biogenesis, and FFA oxidation in HFD-induced obese mice by regulating GPRs [38]. Additionally, we showed that propionate and butyrate administration could directly increase GLP-1 production in db/db mice. Thus, the DHA/EPA-induced SCFAs production may contribute to the beneficial metabolic effect observed in our study.

To confirm the causal relationship between gut microbiota and the hypoglycemic effect of DHA/EPA, we transplanted microbiota from DHA/EPA-fed db/db mice into antibiotic-treated db/db mice fed with a normal diet for 4 weeks. Antibiotic-treated mice rather than germ-free mice were used in our study because germ-free mice have an underdeveloped immune system which may confound our analysis [86]. We showed that transplantation of DHA/EPA altered gut microbiota to recipient mice successfully counteracted hyperglycemia and enhanced insulin production, together with the enriched abundance of Coriobacteriaceae (OTU19898), Barnesiella (OTU136), and Clostridium XlVa (OTU57). Furthermore, we also observed similar changes in fecal metabolites including glutamate, bile acid and SCFAs, with corresponding changes in receptors expressions. Therefore, these data demonstrate DHA/EPA-altered intestinal flora mediate the protective effect for DHA/EPA and provide evidence for an important role of DHA/EPA-induced fecal metabolites in improving glucose homeostasis via crosstalk between gut and organs, including pancreas, liver, and adipose tissue.

Notably, EPA appeared to be more potent than DHA in ameliorating glucose metabolism in db/db mice. Possible explanations are as follows: we first observed that DHA and EPA differentially modulated antimicrobial peptide production in the gut which further led to the differential gut microbiome and metabolome changes. Notably, EPA had a more pronounced antimicrobial activity against LPS-containing Escherichia coli in vitro. Additionally, EPA was more capable of regulating bile acids, promoting propionic/butyric acid production and suppressing glutamate, especially in male mice, which led to more pronounced improvements in β cell apoptosis, hepatic gluconeogenesis, and WAT insulin signaling. We also noted sex differences in intestinal microbiome changes in response to DHA/EPA which could be attributed to sex hormones and sex differences in immune function [87]. In our study, we successfully revealed the metabolic pathway of EPA/DHA induced microbiota using 16S rDNA sequencing and PICRUSt and also provided direct causal evidence. Future researches using shotgun metagenome sequencing, the most solid approach to evaluate the functional profiles of microbial communities, may provide more biological insights.

Although no study has investigated the effect of DHA/EPA supplementation on gut microbiome in T2D patients, some case–control studies demonstrated that compared with non-diabetic controls, T2D patients had higher abundance of Enterobacteriaceae [53] but lower Coriobacteriaceae [75], which was also observed in db/db mice. Importantly, we showed that EPA/DHA could directly alter the growth of these microbiotas in vitro. Therefore, EPA/DHA supplementation is likely to impact the human gut microbiota in a similar way and future clinical studies are warranted to confirm this inference.

Conclusion

In summary, integrated multi-omic analyses uncovered that DHA/EPA supplementation ameliorated glucose homeostasis in the context of diabetes by modulating gut microbiome and metabolome, which further prevented β cell apoptosis, suppressed hepatic gluconeogenesis and induced WAT beiging (Additional file 1: Figure S12). The study offers new insights into the gut microbiota-organs axis as a suitable target for treating metabolic perturbations and also suggests EPA may be a more efficient therapeutic dietary supplement than DHA for diabetic patients.

Methods

Detailed methodologies are available in Additional file 2: Supplementary methods.

Animals and diets

Four-week-old C57BL/KsJ-db/db mice and C57BL/6 mice were purchased from the Model Animal Research Center of Nanjing University (Nanjing, China) and were individually housed in ventilated cages in the animal facility of Zhejiang Chinese Medical University (Hangzhou, China) with a 12-h light/dark cycle, free access to food and water and standard conditions. The db/db mice were randomly assigned to one of three diet groups (12 mice for each group): the normal control diet (AIN93G; Research Diets, Inc., USA) (db/db); control diet supplemented with 1% (w/w) of DHA (purity > 99%; Larodan Fine Chemicals, Malmo, Sweden) (db/db + DHA); and control diet supplemented with 1% (w/w) of EPA (purity > 99%; Larodan Fine Chemicals) (db/db + EPA) for 10 weeks. A group of C57BL/6 J mice (WT) was also fed a control diet for 10 weeks as the positive control. The compositions of diets are shown in Additional file 1: Table S1. After the treatment, mice were euthanized and blood samples were collected. Tissues were carefully dissected and flash-frozen in liquid nitrogen.

Indirect calorimetry

At the 9th week of treatment, metabolic parameters including oxygen consumption and respiratory exchange ratio (RER) were measured by an 8-cage animal monitoring system (PhenoMaster/LabMaster, Bad Homburg, Germany) at room temperature under 12-h day/night cycles.

Glucose, insulin, and pyruvate tolerance tests

OGTT, ITT, and pyruvate tolerance test (PTT) were performed during the last week of the intervention. After overnight fasting, mice were orally gavaged with 66% glucose solution (OGTT, 3 g/kg BW) or injected i.p. with sodium pyruvate (PTT, 2 g/kg BW). For ITT, mice were injected i.p. with insulin (0.75 U/kg BW) after fasting for 6 h. Blood glucose levels in the blood samples from tail veins were measured immediately before (t = 0 min) and at selected time points using an Accu-Check glucose meter (Roche).

Biochemical analyses

The serum glucose, TG, TC, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol were measured using a 7020 automatic biochemistry analyzer (Hitachi Ltd., Tokyo, Japan). The serum insulin, LPS, TNF-α and IL6, intestine GLP1, and hepatic PEPCK, G6PC, and GP levels were detected using commercial enzyme-linked immunosorbent assay kits (Cusabio Biotech Co. Ltd., Wuhan, Hubei, China) according to manufacturer’s protocol.

Gene expression

Total RNA was extracted from the small intestine, WAT, liver, and pancreas using TRIzol. Subsequently, equal amounts of total RNA were reverse-transcribed into cDNA with the RT reagent kit (Takara Bio Inc., Shiga, Japan). The mRNA expression was quantified by a two-step qRT-PCR method [88]. Sequences of the used primers are provided in Additional file 1: Table S2. Expression was normalized to the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase.

Western blot

Total cellular protein from liver and WAT was extracted by lysing frozen tissues in RIPA lysis buffer containing inhibitors of protease and phosphatase. Total proteins were denatured, resolved by SDS-PAGE and then transferred to PVDF membranes (Millipore). The membranes were blocked using Tris-buffered saline Tween containing 5% bovine serum albumin at room temperature for 1 h and subsequently incubated with the primary antibodies against FXR, FOXO1, p-FOXO1, SHP, UCP1, CD137, PRDM16, PPARγ, GLUT4, p-AktSer473, or Akt overnight at 4 °C. The loading control was β-Actin or α-tubulin.

Fecal microbiota transplantation

Fecal transplantation was performed in the last 4 weeks of the dietary intervention based on an established protocol [61]. During the 4 weeks, stools from the donors in different groups (db/db, db/db + DHA, and db/db + EPA) were collected daily under a laminar flow hood in sterile conditions. Every 100 mg fresh stools were resuspended in 1 ml of sterile saline and intensively mixed by vortexing. Subsequently, the mixture was centrifugated at 800 g for 3 min and the supernatant was used as the transplant material which was prepared on the same day of transplantation within 10 min before gavage. Recipient mice were 4-week-old db/db mice fed with a control diet for 6 weeks synchronized with the db/db group. Before fecal transplantation, their endogenous microbiota were depleted by oral gavage with 200 μl mixed antibiotic solution (ampicillin, 1 g/l; metronidazole, 1 g/l; vancomycin, 0.5 g/l; neomycin, 0.5 g/l) daily for 3 days. The recipient mice were fed with a control diet and treated with 200 μl transplant material daily by oral gavage for 4 weeks.

Gut microbiome analysis

Gut microbiome analysis was performed using high-throughput 16S rDNA sequencing as described previously [89]. Briefly, DNA was extracted from fecal samples using the QIAamp Fast DNA Stool Mini Kit. DNA concentration and integrity were determined and the V3–V4 region of the bacterial 16S rRNA was amplified by PCR to construct an amplicon sequencing library. The amplicon was standardized and purified before being paired-end sequenced by an Illumina MiSeq platform. Raw sequencing data were subjected to filtration using Trimmomatic, FLASH, and QIIME software. Sequences were assigned to OTUs at 97% similarity. Representative sequences were chosen for each OTU and taxonomic data were then assigned to each representative sequence using Ribosomal Database Project (RDP) Classifier v.2.2, trained on the Silva database version 123. The OTU table was rarified and Chao 1 metric was calculated by QIIME to estimate α-diversity. Subsequently, the microbial community clustering (β-diversity) was estimated by principal coordinate analysis (PCoA). The linear discriminant analysis (LDA) effect size (LEfSe) analysis was used to identify differential taxa of biological relevance between groups. Non-parametric analysis was performed to assess significant differences in specific taxa between groups using the Kruskall-Wallis test followed by Mann–Whitney test.

Microbial functional profiles prediction

The microbial functional profiles of DHA/EPA-altered gut microbiota was predicted using PICRUSt software (http://picrust.github.io/picrust). This method predicts the gene family abundance from the phylogenetic information with an estimated accuracy of 0.8. Predicted gene class abundances were analyzed at KEGG Orthology group levels 3 [90]. Results from PICRUSt were further analyzed using Statistical Analysis of Metagenomic Profiles (STAMP).

Metabolomic profiling analysis

The sample preparation methods were described previously [91]. UHPLC-Q-Orbitrap-HRMS analyses were performed using a quadrupole-orbitrap mass spectrometer (Q-Exactive, Thermo Fisher Scientific, Waltham, MA, USA) equipped with Dionex 3000 Ultimate UHPLC and autosampler (Thermo Fisher Scientific). Each injected solution was separated with the Acquity UPLC HSS T3 column. The UHPLC analysis followed a gradient elution program. High-resolution mass spectrometry analyses were performed with a heat electrospray ionization (HESI) source under both positive ion mode and negative ion mode. The acquisition mode of quadrupole-orbitrap analyses was set to be the full MS/dd-MS2 (TopN) mode, which is a combination of full MS mode and dd-MS2 mode. The dd-MS2 mode employed an orbitrap resolution of 17,500 with a maximum latency time of 50 ms, high energy collisional dissociation stepped normalized collision energy of 20, 40, and 60, and isolation window of 1.5 m/z. Data analyses were performed using the Xcalibur 4.1 and Compound Discoverer 2.1 software (Thermo Fisher Scientific). The quality control (QC) samples were prepared by pooling of each extracted fecal or serum samples. The Compound Discovery software was used to process the batch normalization automatically using the data from QC samples. Based on the data from mzCloud (https://www.mzcloud.org) and Human Metabolome Database (HMDB) (http://www.hmdb.ca), the structural formula of metabolites were identified according to the accurate mass of their MS and tandem MS spectra. Part of metabolites was verified by standards available in our lab.

After normalization (by weight of fecal or serum samples), all the extracted UHPLC-Q-Orbitrap-HRMS ions were imported into SIMCA software (version 14.1, Umetrics, Umea, Sweden) for statistical analysis. Principle component analysis (PCA) and OPLS-DA with unit variance (UV) scaling were carried out to discriminate DHA/EPA-treated mice from control mice. Fold changes were calculated as mass response ratio between two arbitrary groups (db/db + DHA vs. db/db or db/db + EPA vs. db/db). The variable contribution of the OPLS-DA model was ranked by the variable importance in the projection (VIP). Metabolites passing the threshold of VIP > 1 were considered as significantly different between the DHA/EPA-fed and control mice groups, which were validated at a univariate level with P < 0.05 and fold change ≥ 1.2 or ≤ 0.8. All the annotated differential metabolites were uploaded to MetaboAnalyst (https://www.metaboanalyst.ca/) to identify perturbed pathways according to the KEGG pathway database (https://www.genome.jp/kegg/).

Bacterial culture in vitro

Escherichia coli MG1655 was grown aerobically in LB medium and Coriobacterium glomerans ATCC 49,209 was grown anaerobically in Gifu anaerobic medium (GAM) at 37 °C. At mid-exponential phase of bacterial growth, cultures were added with DHA (200 µM), EPA (200 µM) or vehicle and incubated at 37 °C. The cell density of the cultures was monitored by recording OD600 values of samples taken at various time points until the stationary growth phase.

Statistical analysis

All data were presented as mean ± SEM. Differences between two groups were analyzed by two-tailed Student’s t test. Differences between three or more groups were evaluated through one-way analysis of variance (ANOVA) followed by Tukey’s multiple comparison post-test. Two-way ANOVA was used for data from indirect calorimetry experiments. Heat maps were generated using STAMP. The Spearman’s rho non-parametric correlations between specific taxa and fecal metabolites were calculated using the SAS statistical package (version 9.4, SAS Institute). Gephi Graph Visualization and Manipulation software version 0.9.2 was used to visualize the network. P < 0.05 was considered statistically significant.

Availability of data and materials

OTU tables of gut microbiome and UHPLC-Q-Orbitrap-HRMS metabolomics data are included in this published article (Additional file 3 and Additional file 4). All 16S rRNA gene sequencing reads data has been deposited to the National Center for Biotechnology Information’s Sequence Read Archive under accession number PRJNA609364.

Abbreviations

CA:

Cholic acid

CD:

Control diet

CDCA:

Chenodeoxycholic acid

DCA:

Deoxycholic acid

DHA:

Docosahexaenoic acid

EPA:

Eicosapentaenoic acid

FMT:

Fecal microbiota transplant

GLP-1:

Glucagon-like peptide-1

GPR:

G-protein-coupled receptors

HFD:

High-fat diet

IR:

Insulin resistance

LDA:

Linear discriminant analysis

LEfSe:

Linear discriminant analysis effect size

LPS:

Lipopolysaccharide

OTU:

Operational taxonomic unit

PCoA:

Principal coordinate analysis

PICRUSt:

Phylogenetic Investigation of Communities by Reconstruction of Unobserved States

PUFA:

Polyunsaturated fatty acid

SCFA:

Short-chain fatty acid

T2D:

Type 2 diabetes

TLR4:

Toll-like receptor 4

WAT:

White adipose tissue

References

  1. 1.

    International Diabetes Federation. IDF diabetes atlas. 9th ed. Brussels: International Diabetes Federation; 2019.

    Google Scholar 

  2. 2.

    Finlay BB. Are noncommunicable diseases communicable? Science. 2020;367(6475):250–1.

    CAS  PubMed  Article  Google Scholar 

  3. 3.

    Saad MJA, Santos A, Prada PO. Linking gut microbiota and inflammation to obesity and insulin resistance. Physiology. 2016;31(4):283–93.

    CAS  PubMed  Article  Google Scholar 

  4. 4.

    Liang X, Bushman Frederic D, FitzGerald GA. Time in motion: The molecular clock meets the microbiome. Cell. 2014;159(3):469–70.

    CAS  PubMed  Article  Google Scholar 

  5. 5.

    Scott KP, Gratz SW, Sheridan PO, Flint HJ, Duncan SH. The influence of diet on the gut microbiota. Pharmacol Res. 2013;69(1):52–60.

    CAS  PubMed  Article  Google Scholar 

  6. 6.

    Kennedy A, Martinez K, Chuang C-C, LaPoint K, McIntosh M. Saturated fatty acid-mediated inflammation and insulin resistance in adipose tissue: Mechanisms of action and implications. J Nutr. 2008;139(1):1–4.

    PubMed  Article  CAS  Google Scholar 

  7. 7.

    Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM, et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet–induced obesity and diabetes in mice. Diabetes. 2008;57(6):1470–81.

    CAS  PubMed  Article  Google Scholar 

  8. 8.

    Buckley JD, Howe PRC. Anti-obesity effects of long-chain omega-3 polyunsaturated fatty acids. Obes Rev. 2009;10(6):648–59.

    CAS  PubMed  Article  Google Scholar 

  9. 9.

    Calder PC. n−3 Polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr. 2006;83(6 Suppl):1505S-S1519.

    CAS  PubMed  Article  Google Scholar 

  10. 10.

    Caesar R, Tremaroli V, Kovatcheva-Datchary P, Cani Patrice D, Bäckhed F. Crosstalk between gut microbiota and dietary lipids aggravates WAT inflammation through TLR signaling. Cell Metab. 2015;22(4):658–68.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  11. 11.

    Zhuang P, Shou Q, Wang W, He L, Wang J, Chen J, et al. Essential fatty acids linoleic acid and α-linolenic acid sex-dependently regulate glucose homeostasis in obesity. Mol Nutr Food Res. 2018;62(17):e1800448.

    PubMed  Article  CAS  Google Scholar 

  12. 12.

    Bhaswant M, Poudyal H, Brown L. Mechanisms of enhanced insulin secretion and sensitivity with n-3 unsaturated fatty acids. J Nutr Biochem. 2015;26(6):571–84.

    CAS  PubMed  Article  Google Scholar 

  13. 13.

    Neschen S, Morino K, Rossbacher JC, Pongratz RL, Cline GW, Sono S, et al. Fish oil regulates adiponectin secretion by a peroxisome proliferator–activated receptor-γ–dependent mechanism in mice. Diabetes. 2006;55(4):924–8.

    CAS  PubMed  Article  Google Scholar 

  14. 14.

    Pinel A, Pitois E, Rigaudiere J-P, Jouve C, De Saint-Vincent S, Laillet B, et al. EPA prevents fat mass expansion and metabolic disturbances in mice fed with a Western diet. J Lipid Res. 2016;57(8):1382–97.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  15. 15.

    Huber J, Löffler M, Bilban M, Reimers M, Kadl A, Todoric J, et al. Prevention of high-fat diet-induced adipose tissue remodeling in obese diabetic mice by n-3 polyunsaturated fatty acids. Int J Obes. 2007;31(6):1004–13.

    CAS  Article  Google Scholar 

  16. 16.

    Kalupahana NS, Claycombe K, Newman SJ, Stewart T, Siriwardhana N, Matthan N, et al. Eicosapentaenoic acid prevents and reverses insulin resistance in high-fat diet-induced obese mice via modulation of adipose tissue inflammation. J Nutr. 2010;140(11):1915–22.

    CAS  PubMed  Article  Google Scholar 

  17. 17.

    Oh DY, Talukdar S, Bae EJ, Imamura T, Morinaga H, Fan W, et al. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell. 2010;142(5):687–98.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  18. 18.

    White PJ, Arita M, Taguchi R, Kang JX, Marette A. Transgenic restoration of long-chain n-3 fatty acids in insulin target tissues improves resolution capacity and alleviates obesity-linked inflammation and insulin resistance in high-fat-fed mice. Diabetes. 2010;59(12):3066–73.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  19. 19.

    Martins AR, Crisma AR, Masi LN, Amaral CL, Marzuca-Nassr GN, Bomfim LHM, et al. Attenuation of obesity and insulin resistance by fish oil supplementation is associated with improved skeletal muscle mitochondrial function in mice fed a high-fat diet. J Nutr Biochem. 2018;55:76–88.

    CAS  PubMed  Article  Google Scholar 

  20. 20.

    Ghosh S, DeCoffe D, Brown K, Rajendiran E, Estaki M, Dai C, et al. Fish oil attenuates omega-6 polyunsaturated fatty acid-induced dysbiosis and infectious colitis but impairs LPS dephosphorylation activity causing sepsis. PloS One. 2013;8(2):e55468.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  21. 21.

    Yu H-N, Zhu J, Pan W-S, Shen S-R, Shan W-G, Das UN. Effects of fish oil with a high content of n-3 polyunsaturated fatty acids on mouse gut microbiota. Arch Med Res. 2014;45(3):195–202.

    CAS  PubMed  Article  Google Scholar 

  22. 22.

    Mujico JR, Baccan GC, Gheorghe A, Díaz LE, Marcos A. Changes in gut microbiota due to supplemented fatty acids in diet-induced obese mice. Br J Nutr. 2013;110(4):711–20.

    CAS  PubMed  Article  Google Scholar 

  23. 23.

    Caesar R, Reigstad CS, Bäckhed HK, Reinhardt C, Ketonen M, Östergren Lundén G, et al. Gut-derived lipopolysaccharide augments adipose macrophage accumulation but is not essential for impaired glucose or insulin tolerance in mice. Gut. 2012;61(12):1701–7.

    CAS  PubMed  Article  Google Scholar 

  24. 24.

    Rabot S, Membrez M, Bruneau A, Gérard P, Harach T, Moser M, et al. Germ-free C57BL/6J mice are resistant to high-fat-diet-induced insulin resistance and have altered cholesterol metabolism. FASEB J. 2010;24(12):4948–59.

    CAS  PubMed  Google Scholar 

  25. 25.

    Thomas RM, Jobin C. Microbiota in pancreatic health and disease: the next frontier in microbiome research. Nat Rev Gastroenterol Hepatol. 2020;17(1):53–64.

    PubMed  Article  Google Scholar 

  26. 26.

    Albillos A, de Gottardi A, Rescigno M. The gut-liver axis in liver disease: Pathophysiological basis for therapy. J Hepatol. 2020;72(3):558–77.

    CAS  PubMed  Article  Google Scholar 

  27. 27.

    Tsukumo DML, Carvalho-Filho MA, Carvalheira JBC, Prada PO, Hirabara SM, Schenka AA, et al. Loss-of-function mutation in Toll-Like Receptor 4 prevents diet-induced obesity and insulin resistance. Diabetes. 2007;56(8):1986–98.

    CAS  PubMed  Article  Google Scholar 

  28. 28.

    Pingitore A, Chambers ES, Hill T, Maldonado IR, Liu B, Bewick G, et al. The diet-derived short chain fatty acid propionate improves beta-cell function in humans and stimulates insulin secretion from human islets in vitro. Diabetes Obes Metab. 2017;19(2):257–65.

    CAS  PubMed  Article  Google Scholar 

  29. 29.

    Yadav H, Lee J-H, Lloyd J, Walter P, Rane SG. Beneficial metabolic effects of a probiotic via butyrate-induced GLP-1 hormone secretion. J Biol Chem. 2013;288(35):25088–97.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  30. 30.

    Layden BT, Angueira AR, Brodsky M, Durai V, Lowe WL Jr. Short chain fatty acids and their receptors: new metabolic targets. Transl Res. 2013;161(3):131–40.

    CAS  PubMed  Article  Google Scholar 

  31. 31.

    Selwyn FP, Csanaky IL, Zhang Y, Klaassen CD. Importance of large intestine in regulating bile acids and glucagon-like peptide-1 in germ-free mice. Drug Metab Dispos. 2015;43(10):1544–56.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  32. 32.

    Wahlström A, Sayin Sama I, Marschall H-U, Bäckhed F. Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metab. 2016;24(1):41–50.

    PubMed  Article  CAS  Google Scholar 

  33. 33.

    Liu R, Hong J, Xu X, Feng Q, Zhang D, Gu Y, et al. Gut microbiome and serum metabolome alterations in obesity and after weight-loss intervention. Nat Med. 2017;23(7):859–68.

    CAS  PubMed  Article  Google Scholar 

  34. 34.

    Canfora EE, Meex RCR, Venema K, Blaak EE. Gut microbial metabolites in obesity, NAFLD and T2DM. Nat Rev Endocrinol. 2019;15(5):261–73.

    CAS  PubMed  Article  Google Scholar 

  35. 35.

    He K, Du S, Xun P, Sharma S, Wang H, Zhai F, et al. Consumption of monosodium glutamate in relation to incidence of overweight in Chinese adults: China Health and Nutrition Survey (CHNS). Am J Clin Nutr. 2011;93(6):1328–36.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  36. 36.

    Di Cairano ES, Davalli AM, Perego L, Sala S, Sacchi VF, La Rosa S, et al. The glial glutamate transporter 1 (GLT1) is expressed by pancreatic beta-cells and prevents glutamate-induced beta-cell death. J Biol Chem. 2011;286(16):14007–18.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  37. 37.

    Shapiro H, Kolodziejczyk AA, Halstuch D, Elinav E. Bile acids in glucose metabolism in health and disease. J Exp Med. 2018;215(2):383–96.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  38. 38.

    Lu Y, Fan C, Li P, Lu Y, Chang X, Qi K. Short chain fatty acids prevent high-fat-diet-induced obesity in mice by regulating G protein-coupled receptors and gut microbiota. Sci Rep. 2016;6(1):37589.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  39. 39.

    Jeremic N, Chaturvedi P, Tyagi SC. Browning of white fat: Novel insight into factors, mechanisms, and therapeutics. J Cell Physiol. 2017;232(1):61–8.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  40. 40.

    Zhuang P, Lu Y, Shou Q, Mao L, He L, Wang J, et al. Differential anti-adipogenic effects of eicosapentaenoic and docosahexaenoic acids in obesity. Mol Nutr Food Res. 2019;63(14):e1801135.

    PubMed  Article  CAS  Google Scholar 

  41. 41.

    Kopf T, Schmitz G. Analysis of non-esterified fatty acids in human samples by solid-phase-extraction and gas chromatography/mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2013;938:22–6.

    CAS  PubMed  Article  Google Scholar 

  42. 42.

    Flachs P, Rossmeisl M, Kopecky J. The effect of n-3 fatty acids on glucose homeostasis and insulin sensitivity. Physiol Res. 2014;63(Suppl 1):S93–118.

    CAS  PubMed  Article  Google Scholar 

  43. 43.

    Flachs P, Mohamed-Ali V, Horakova O, Rossmeisl M, Hosseinzadeh-Attar MJ, Hensler M, et al. Polyunsaturated fatty acids of marine origin induce adiponectin in mice fed a high-fat diet. Diabetologia. 2006;49(2):394–7.

    CAS  PubMed  Article  Google Scholar 

  44. 44.

    Lanza IR, Blachnio-Zabielska A, Johnson ML, Schimke JM, Jakaitis DR, Lebrasseur NK, et al. Influence of fish oil on skeletal muscle mitochondrial energetics and lipid metabolites during high-fat diet. Am J Physiol Endocrinol Metab. 2013;304(12):E1391–403.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  45. 45.

    Rossmeisl M, Jilkova ZM, Kuda O, Jelenik T, Medrikova D, Stankova B, et al. Metabolic effects of n-3 PUFA as phospholipids are superior to triglycerides in mice fed a high-fat diet: possible role of endocannabinoids. PloS One. 2012;7(6):e38834.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  46. 46.

    Ruzickova J, Rossmeisl M, Prazak T, Flachs P, Sponarova J, Vecka M, et al. Omega-3 PUFA of marine origin limit diet-induced obesity in mice by reducing cellularity of adipose tissue. Lipids. 2004;39(12):1177–85.

    CAS  PubMed  Article  Google Scholar 

  47. 47.

    Storlien LH, Jenkins AB, Chisholm DJ, Pascoe WS, Khouri S, Kraegen EW. Influence of dietary fat composition on development of insulin resistance in rats: Relationship to muscle triglyceride and ω-3 fatty acids in muscle phospholipid. Diabetes. 1991;40(2):280–9.

    CAS  PubMed  Article  Google Scholar 

  48. 48.

    Podolin DA, Gayles EC, Wei Y, Thresher JS, Pagliassotti MJ. Menhaden oil prevents but does not reverse sucrose-induced insulin resistance in rats. Am J Physiol Regul Integr Comp Physiol. 1998;274(3):R840–8.

    CAS  Article  Google Scholar 

  49. 49.

    Bidu C, Escoula Q, Bellenger S, Spor A, Galan M, Geissler A, et al. The transplantation of ω3 PUFA–altered gut microbiota of fat-1 mice to wild-type littermates prevents obesity and associated metabolic disorders. Diabetes. 2018;67(8):1512–23.

    CAS  PubMed  Article  Google Scholar 

  50. 50.

    Younge N, Yang Q, Seed PC. Enteral high fat-polyunsaturated fatty acid blend alters the pathogen composition of the intestinal microbiome in premature infants with an enterostomy. J Pediatr. 2017;181:93-101.e6.

    CAS  PubMed  Article  Google Scholar 

  51. 51.

    Blin C, Passet V, Touchon M, Rocha EPC, Brisse S. Metabolic diversity of the emerging pathogenic lineages of Klebsiella pneumoniae. Environ Microbiol. 2017;19(5):1881–98.

    CAS  PubMed  Article  Google Scholar 

  52. 52.

    Tsatsaronis JA, Walker MJ, Sanderson-Smith ML. Host responses to group a streptococcus: cell death and inflammation. PLoS Pathog. 2014;10(8):e1004266.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  53. 53.

    Chen Q, Ma X, Li C, Shen Y, Zhu W, Zhang Y, et al. Enteric phageome alterations in patients with type 2 diabetes. Front Cell Infect Microbiol. 2021;10:575084.

    PubMed  PubMed Central  Article  Google Scholar 

  54. 54.

    Li J, Sung CYJ, Lee N, Ni Y, Pihlajamäki J, Panagiotou G, et al. Probiotics modulated gut microbiota suppresses hepatocellular carcinoma growth in mice. Proc Natl Acad Sci U S A. 2016;113(9):E1306–15.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  55. 55.

    Karlsson FH, Tremaroli V, Nookaew I, Bergström G, Behre CJ, Fagerberg B, et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature. 2013;498(7452):99–103.

    CAS  PubMed  Article  Google Scholar 

  56. 56.

    Geurts L, Lazarevic V, Derrien M, Everard A, Van Roye M, Knauf C, et al. Altered gut microbiota and endocannabinoid system tone in obese and diabetic leptin-resistant mice: impact on apelin regulation in adipose tissue. Front Microbiol. 2011;2:149.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  57. 57.

    Song JJ, Tian WJ, Kwok L-Y, Wang YL, Shang YN, Menghe B, et al. Effects of microencapsulated Lactobacillus plantarum LIP-1 on the gut microbiota of hyperlipidaemic rats. Br J Nutr. 2017;118(7):481–92.

    CAS  PubMed  Article  Google Scholar 

  58. 58.

    Berry D, Reinisch W. Intestinal microbiota: a source of novel biomarkers in inflammatory bowel diseases? Best Pract Res Clin Gastroenterol. 2013;27(1):47–58.

    CAS  PubMed  Article  Google Scholar 

  59. 59.

    Weiss GA, Chassard C, Hennet T. Selective proliferation of intestinal Barnesiella under fucosyllactose supplementation in mice. Br J Nutr. 2014;111(9):1602–10.

    CAS  PubMed  Article  Google Scholar 

  60. 60.

    Herp S, Brugiroux S, Garzetti D, Ring D, Jochum LM, Beutler M, et al. Mucispirillum schaedleri antagonizes Salmonella Virulence to protect mice against colitis. Cell Host Microbe. 2019;25(5):681-94.e8.

    CAS  PubMed  Article  Google Scholar 

  61. 61.

    Chang C-J, Lin C-S, Lu C-C, Martel J, Ko Y-F, Ojcius DM, et al. Ganoderma lucidum reduces obesity in mice by modulating the composition of the gut microbiota. Nat Commun. 2015;6:7489.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  62. 62.

    Lam YY, Ha CWY, Hoffmann JMA, Oscarsson J, Dinudom A, Mather TJ, et al. Effects of dietary fat profile on gut permeability and microbiota and their relationships with metabolic changes in mice. Obesity. 2015;23(7):1429–39.

    CAS  PubMed  Article  Google Scholar 

  63. 63.

    Louis P, Flint HJ. Formation of propionate and butyrate by the human colonic microbiota. Environ Microbiol. 2017;19(1):29–41.

    CAS  Article  Google Scholar 

  64. 64.

    Bui TPN, Shetty SA, Lagkouvardos I, Ritari J, Chamlagain B, Douillard FP, et al. Comparative genomics and physiology of the butyrate-producing bacterium Intestinimonas butyriciproducens. Environ Microbiol Rep. 2016;8(6):1024–37.

    CAS  PubMed  Article  Google Scholar 

  65. 65.

    Kong C, Gao R, Yan X, Huang L, Qin H. Probiotics improve gut microbiota dysbiosis in obese mice fed a high-fat or high-sucrose diet. Nutrition. 2019;60:175–84.

    CAS  PubMed  Article  Google Scholar 

  66. 66.

    Roberfroid M, Gibson GR, Hoyles L, McCartney AL, Rastall R, Rowland I, et al. Prebiotic effects: metabolic and health benefits. Br J Nutr. 2010;104(Suppl 2):S1-63.

    CAS  PubMed  Article  Google Scholar 

  67. 67.

    Guarner F, Perdigon G, Corthier G, Salminen S, Koletzko B, Morelli L. Should yoghurt cultures be considered probiotic? Br J Nutr. 2007;93(6):783–6.

    Article  CAS  Google Scholar 

  68. 68.

    Bajaj JS, Heuman DM, Hylemon PB, Sanyal AJ, Puri P, Sterling RK, et al. Randomized clinical trial: lactobacillus gg modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis. Aliment Pharmacol Ther. 2014;39(10):1113–25.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  69. 69.

    Kaliannan K, Wang B, Li X-Y, Kim K-J, Kang JX. A host-microbiome interaction mediates the opposing effects of omega-6 and omega-3 fatty acids on metabolic endotoxemia. Sci Rep. 2015;5:11276.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  70. 70.

    Hermanussen M, García AP, Sunder M, Voigt M, Salazar V, Tresguerres JAF. Obesity, voracity, and short stature: the impact of glutamate on the regulation of appetite. Eur J Clin Nutr. 2006;60(1):25–31.

    CAS  PubMed  Article  Google Scholar 

  71. 71.

    Gralka E, Luchinat C, Tenori L, Ernst B, Thurnheer M, Schultes B. Metabolomic fingerprint of severe obesity is dynamically affected by bariatric surgery in a procedure-dependent manner. Am J Clin Nutr. 2015;102(6):1313–22.

    CAS  PubMed  Article  Google Scholar 

  72. 72.

    Banday VS, Lejon K. Elevated systemic glutamic acid level in the non-obese diabetic mouse is Idd linked and induces beta cell apoptosis. Immunology. 2017;150(2):162–71.

    CAS  PubMed  Article  Google Scholar 

  73. 73.

    Ottosson F, Brunkwall L, Ericson U, Nilsson PM, Almgren P, Fernandez C, et al. Connection between BMI-related plasma metabolite profile and gut microbiota. J Clin Endocrinol Metab. 2018;103(4):1491–501.

    PubMed  Article  Google Scholar 

  74. 74.

    Mar Rodríguez M, Pérez D, Javier Chaves F, Esteve E, Marin-Garcia P, Xifra G, et al. Obesity changes the human gut mycobiome. Sci Rep. 2015;5:14600.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  75. 75.

    Liu H, Zhang H, Wang X, Yu X, Hu C, Zhang X. The family Coriobacteriaceae is a potential contributor to the beneficial effects of Roux-en-Y gastric bypass on type 2 diabetes. Surg Obes Relat Dis. 2018;14(5):584–93.

    PubMed  Article  Google Scholar 

  76. 76.

    Stackebrandt E, Zeytun A, Lapidus A, Nolan M, Lucas S, Hammon N, et al. Complete genome sequence of Coriobacterium glomerans type strain (PW2T) from the midgut of Pyrrhocoris apterus L. (red soldier bug). Stand Genomic Sci. 2013;8:15–25.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  77. 77.

    Wahlström A, Kovatcheva-Datchary P, Ståhlman M, Bäckhed F, Marschall HU. Crosstalk between bile acids and gut microbiota and its impact on farnesoid X receptor signalling. Digest Dis. 2017;35(3):246–50.

    Article  Google Scholar 

  78. 78.

    Sayin Sama I, Wahlström A, Felin J, Jäntti S, Marschall H-U, Bamberg K, et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab. 2013;17(2):225–35.

    CAS  PubMed  Article  Google Scholar 

  79. 79.

    Zhang Y, Lee FY, Barrera G, Lee H, Vales C, Gonzalez FJ, et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci U S A. 2006;103(4):1006–11.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  80. 80.

    Yamagata K, Daitoku H, Shimamoto Y, Matsuzaki H, Hirota K, Ishida J, et al. Bile acids regulate gluconeogenic gene expression via small heterodimer partner-mediated repression of hepatocyte nuclear factor 4 and Foxo1. J Biol Chem. 2004;279(22):23158–65.

    CAS  PubMed  Article  Google Scholar 

  81. 81.

    Caprio S, Perry R, Kursawe R. Adolescent obesity and insulin resistance: Roles of ectopic fat accumulation and adipose inflammation. Gastroenterology. 2017;152(7):1638–46.

    CAS  PubMed  Article  Google Scholar 

  82. 82

    Al-Lahham SA, Roelofsen H, Rezaee F, Weening D, Hoek A, Vonk R, et al. Propionic acid affects immune status and metabolism in adipose tissue from overweight subjects. Eur J Clin Invest. 2012;42(4):357–64.

    CAS  PubMed  Article  Google Scholar 

  83. 83.

    Wang X, He G, Peng Y, Zhong W, Wang Y, Zhang B. Sodium butyrate alleviates adipocyte inflammation by inhibiting NLRP3 pathway. Sci Rep. 2015;5:12676.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  84. 84.

    Ohira H, Fujioka Y, Katagiri C, Mamoto R, Aoyama-Ishikawa M, Amako K, et al. Butyrate attenuates inflammation and lipolysis generated by the interaction of adipocytes and macrophages. J Atheroscler Thromb. 2013;20(5):425–42.

    CAS  PubMed  Article  Google Scholar 

  85. 85.

    Perry RJ, Peng L, Barry NA, Cline GW, Zhang D, Cardone RL, et al. Acetate mediates a microbiome–brain–β-cell axis to promote metabolic syndrome. Nature. 2016;534:213.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  86. 86.

    Hooper LV, Littman DR, Macpherson AJ. Interactions between the microbiota and the immune system. Science. 2012;336(6086):1268–73.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  87. 87.

    Bolnick DI, Snowberg LK, Hirsch PE, Lauber CL, Org E, Parks B, et al. Individual diet has sex-dependent effects on vertebrate gut microbiota. Nat Comm. 2014;5:4500.

    CAS  Article  Google Scholar 

  88. 88.

    Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 2009;55(4):611–22.

    CAS  PubMed  Article  Google Scholar 

  89. 89.

    Ye J, Lv L, Wu W, Li Y, Shi D, Fang D, et al. Butyrate protects mice against methionine-choline-deficient diet-induced non-alcoholic steatohepatitis by improving gut barrier function, attenuating inflammation and reducing endotoxin levels. Front Microbiol. 2018;9:1967.

    PubMed  PubMed Central  Article  Google Scholar 

  90. 90.

    Langille MGI, Zaneveld J, Caporaso JG, McDonald D, Knights D, Reyes JA, et al. Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences. Nat Biotechnol. 2013;31(9):814–21.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  91. 91.

    Cesbron N, Royer AL, Guitton Y, Sydor A, Le Bizec B, Dervilly-Pinel G. Optimization of fecal sample preparation for untargeted LC-HRMS based metabolomics. Metabolomics. 2017;13(8):99.

    Article  CAS  Google Scholar 

Download references

Funding

This work was supported by the National Natural Science Foundation of China (grant number 81773419) and the China Postdoctoral Science Foundation (grant number 2020M681869).

Author information

Affiliations

Authors

Contributions

PZ, YZ, and JJ designed to the study. PZ, YZ, QS, HL, XW, WW, WJ, XC, and FW acquired data and carried out the experiment work; PZ, HL, FW, and JJ performed the statistical analysis and interpreted the results. PZ wrote the manuscript. YZ and JJ are the guarantors of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. All authors read, reviewed, edited, and approved the final manuscript.

Corresponding authors

Correspondence to Yu Zhang or Jingjing Jiao.

Ethics declarations

Ethics approval and consent to participate

The animal experimentation was approved by the Zhejiang Chinese Medical University Animal Care and Use Committee (approval number ZSLL-2018–016).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Zhuang, P., Li, H., Jia, W. et al. Eicosapentaenoic and docosahexaenoic acids attenuate hyperglycemia through the microbiome-gut-organs axis in db/db mice. Microbiome 9, 185 (2021). https://doi.org/10.1186/s40168-021-01126-6

Download citation

Keywords

  • Eicosapentaenoic acid
  • Docosahexaenoic acid
  • Gut microbiome
  • Gut metabolome
  • Diabetes